RAX2
Basic information
Region (hg38): 19:3769089-3772228
Previous symbols: [ "RAXL1" ]
Links
Phenotypes
GenCC
Source:
- retinitis pigmentosa (Moderate), mode of inheritance: AR
- cone-rod dystrophy (Supportive), mode of inheritance: AD
- retinitis pigmentosa 95 (Limited), mode of inheritance: AR
- cone-rod dystrophy 11 (Strong), mode of inheritance: AD
- cone-rod dystrophy 11 (Strong), mode of inheritance: AD
- retinitis pigmentosa 95 (Strong), mode of inheritance: AR
- retinitis pigmentosa (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Cone-rod dystrophy 11; Retinitis pigmentosa 95 | AD/AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Ophthalmologic | 15028672; 30377383 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (203 variants)
- not_specified (42 variants)
- Cone-rod_dystrophy_11 (30 variants)
- Age_related_macular_degeneration_6 (25 variants)
- Retinal_dystrophy (17 variants)
- Retinitis_pigmentosa_95 (7 variants)
- RAX2-related_disorder (3 variants)
- Macular_degeneration (2 variants)
- Cone-Rod_Dystrophy,_Dominant (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the RAX2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001319074.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 60 | 62 | ||||
| missense | 112 | 126 | ||||
| nonsense | 3 | |||||
| start loss | 0 | |||||
| frameshift | 11 | |||||
| splice donor/acceptor (+/-2bp) | 1 | |||||
| Total | 7 | 5 | 120 | 68 | 3 |
Highest pathogenic variant AF is 0.000045451055
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| RAX2 | protein_coding | protein_coding | ENST00000555633 | 2 | 3147 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00829 | 0.581 | 108910 | 0 | 3 | 108913 | 0.0000138 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.169 | 118 | 123 | 0.957 | 0.00000905 | 1126 |
| Missense in Polyphen | 53 | 56.919 | 0.93115 | 528 | ||
| Synonymous | 0.877 | 50 | 58.5 | 0.854 | 0.00000436 | 421 |
| Loss of Function | 0.208 | 3 | 3.41 | 0.879 | 1.47e-7 | 38 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000667 | 0.0000667 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000107 | 0.0000104 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: May be involved in modulating the expression of photoreceptor specific genes. Binds to the Ret-1 and Bat-1 element within the rhodopsin promoter. {ECO:0000269|PubMed:15028672}.;
- Disease
- DISEASE: Macular degeneration, age-related, 6 (ARMD6) [MIM:613757]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:15028672}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy 11 (CORD11) [MIM:610381]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors. {ECO:0000269|PubMed:15028672}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.175
Haploinsufficiency Scores
- pHI
- 0.209
- hipred
- N
- hipred_score
- 0.215
- ghis
- 0.465
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.228
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- visual perception;positive regulation of transcription by RNA polymerase II;response to stimulus
- Cellular component
- nucleus
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific